Market Research Logo

Cough - Pipeline Review, H2 2016

Cough - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Cough - Pipeline Review, H2 2016’, provides an overview of the Cough pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Cough
    • The report reviews pipeline therapeutics for Cough by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Cough therapeutics and enlists all their major and minor projects
    • The report assesses Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Cough
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Cough
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Cough Overview
    Therapeutics Development
    Pipeline Products for Cough - Overview
    Pipeline Products for Cough - Comparative Analysis
    Cough - Therapeutics under Development by Companies
    Cough - Therapeutics under Investigation by Universities/Institutes
    Cough - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Cough - Products under Development by Companies
    Cough - Products under Investigation by Universities/Institutes
    Cough - Companies Involved in Therapeutics Development
    Afferent Pharmaceuticals, Inc.
    Alitair Pharmaceuticals, Inc.
    Alveonix AG
    AstraZeneca Plc
    AusBio Ltd
    Charleston Laboratories, Inc.
    Conrig Pharma ApS
    Daewoong Pharmaceutical Co., Ltd.
    GlaxoSmithKline Plc
    Glenmark Pharmaceuticals Ltd.
    GW Pharmaceuticals Plc
    Hyundai Pharmaceutical Co., Ltd.
    Johnson & Johnson
    NeRRe Therapeutics Ltd
    Orbis Biosciences Inc
    Patara Pharma, Inc.
    Pila Pharma AB
    Vernalis Plc
    Cough - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    Ax-8 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    benzonatate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CCP-05 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CCP-06 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CCP-07 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CCP-08 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CLAT-313 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    codeine + guaifenesin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cromolyn sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DWJ-1340 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GRC-17536 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2339345 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    guaifenesin + hydrocodone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    guaifenesin ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JNJ-39729209 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lesogaberan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    levodropropizine CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MD-990 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MK-7264 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NEO-5937 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    orvepitant maleate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S-1226 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ST-015 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    XEND-0501 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cough - Dormant Projects
    Cough - Discontinued Products
    Cough - Product Development Milestones
    Featured News & Press Releases
    Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
    May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference
    May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors
    Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference
    Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study
    Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study
    Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
    Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing
    Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial
    Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
    Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing
    Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet
    Sep 09, 2014: Charleston Laboratories Announces Key Clinical Updates for Novel Drug
    Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
    Apr 29, 2014: Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Cough, H2 2016
    Number of Products under Development for Cough - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016
    Cough - Pipeline by Alitair Pharmaceuticals, Inc., H2 2016
    Cough - Pipeline by Alveonix AG, H2 2016
    Cough - Pipeline by AstraZeneca Plc, H2 2016
    Cough - Pipeline by AusBio Ltd, H2 2016
    Cough - Pipeline by Charleston Laboratories, Inc., H2 2016
    Cough - Pipeline by Conrig Pharma ApS, H2 2016
    Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
    Cough - Pipeline by GlaxoSmithKline Plc, H2 2016
    Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
    Cough - Pipeline by GW Pharmaceuticals Plc, H2 2016
    Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
    Cough - Pipeline by Johnson & Johnson, H2 2016
    Cough - Pipeline by NeRRe Therapeutics Ltd, H2 2016
    Cough - Pipeline by Orbis Biosciences Inc, H2 2016
    Cough - Pipeline by Patara Pharma, Inc., H2 2016
    Cough - Pipeline by Pila Pharma AB, H2 2016
    Cough - Pipeline by Vernalis Plc, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Cough - Dormant Projects, H2 2016
    Cough - Dormant Projects (Contd..1), H2 2016
    Cough - Dormant Projects (Contd..2), H2 2016
    Cough - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Cough, H2 2016
    Number of Products under Development for Cough - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report